Natco Pharma: Q2 FY26 Performance Review and Dividend Announcement

Key Financial Highlights (YoY Comparison) Net Profit: The company reported a consolidated net profit of ₹518 crore, marking a 23.5% decline from the ₹677.3 crore posted in the corresponding quarter of the previous fiscal year (Q2 FY25). Revenue from Operations: Quarterly revenue saw a marginal dip, settling at ₹1,363 crore compared to ₹1,371 crore in the prior-year period. EBITDA: Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) witnessed a sharp 28% contraction, falling to ₹579 crore from ₹804 crore in Q2 FY25. Profitability Analysis The decline in operational profitability was the most significant factor in the quarterly performance. The EBITDA margin narrowed substantially to 42.5% for the quarter. This represents a significant erosion of 1,610 basis points from the robust 58.6% margin reported in the same period last year, indicating increased cost pressures or shifts in the product mix impacting profitability. Shareholder Returns (Interim Dividend) Despite the earnings pressure, the Board of Directors has approved the declaration of an interim dividend for the financial year 2025-26. Dividend per Share: ₹1.50 per equity share (on a face value of ₹2 each). Record Date: The company has fixed November 20, 2025, as the record date to determine shareholder eligibility. Payment Date: Dividend payments will commence on or after November 28, 2025. Market Context Following the earnings announcement, the company's stock reacted negatively. Shares of Natco Pharma Ltd. were trading 2% lower at ₹810. This contributes to a challenging trend for the stock, which has seen its value decline by over 40% year-to-date in 2025.